8 September 2012 - 60P has published the first description of the potential market for dengue drugs in Antiviral Research (Dow and Mora, 2012, Antiviral Research 96:203-212). Based on publicly available information regarding the medical costs and lost productivity associated with clinical cases of dengue, we estimate that annual economic burden of dengue is at least $1.7 billion. Assuming that the economic burden relieved by future dengue drugs was shared between national governments and manufacturers, we estimate that the potential market for dengue drugs is $338 million annually.
April 9 2013 - A recent report suggests that the incidence of dengue may have been under-estimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upwards.
January 1, 2014 - 60P recently established a subsidiary, 60P Australia, Pty Ltd. 60P Australia will take the lead in continuing the company's development of dengue therapeutics.
April 1 2014 - 60P has entered into a research collaboration agreement with the Duke-National University of Singapore Graduate Medical School to investigate the utility of different combinations of dengue drugs including in vitro and in animal models. Dengue, like other viral diseases such as hepatitis C and HIV, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. The studies will be performed in the laboratory of Dr Subhash Vasudevan.
June 11, 2014 - Recently, one of 60P's partners, Duke-National University of Singapore Graduate Medical School and its collaborators, completed a Phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend towards faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.
July 30, 2014 - 60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever. 60P is preparing to conduct a Phase II clinical trial beginning in the second half of 2015.
April 28, 2015 - 60P recently entered into a cooperative research and development agreement with the United States Army to commercialize 60P003 (INN name is tafenoquine) for malaria prophylaxis.
May 1, 2015 - 60P was recently invited to present at the Cavendish Global Forum in La Jolla, California, on May 11-14, 2015.
August 31, 2015 - 60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.
December 11, 2015 - 60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc, in support of our drug development program for tropical diseases.